Endothelial inhibitory modulation on the contractile responses to alpha 2-adrenergic agonists.
Gil-Gastelum
O
O
Escuela Superior de Medicina, IPN. Sección de Posgrado e Investigación, Plan de San Luis y Salvador Díaz Mirón s/n, Col. Casco de Sto Tomás, C.P. 11340, México, D.F., México. farmalab@tutopia.com
Valencia
I
I
Larios
F J
FJ
Castillo
E F
EF
Castillo
C
C
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D000068438:Brimonidine Tartrate; D004730:Endothelium, Vascular / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D052250:Nitric Oxide Synthase Type III; D010109:Oxymetazoline / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D004791:Enzyme Inhibitors; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D010109:Oxymetazoline; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat; D019331:NG-Nitroarginine Methyl Ester